Earnings PreviewBOLT
BOLT Biotherapeutics Heads Into Earnings with Shorts in Full Retreat
Bolt Biotherapeutics reports Q1 2026 results today with one striking data point: short sellers have largely abandoned their positions, even as the stock remains near $4.78 and the company continues to burn cash. The…
1 min read
